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The morphological alterations of cortical lamination observed in mouse models of develop-
mental hypothyroidism prompted the recognition that these experimental changes resem-
bled the brain lesions of children with autism; this led to recent studies showing that
maternal thyroid hormone deficiency increases fourfold the risk of autism spectrum disor-
ders (ASD), offering for the first time the possibility of prevention of some forms of ASD.
For ethical reasons, the role of thyroid hormones on brain development is currently studied
using animal models, usually mice and rats. Although mammals have in common many
basic developmental principles regulating brain development, as well as fundamental basic
mechanisms that are controlled by similar metabolic pathway activated genes, there are
also important differences. For instance, the rodent cerebral cortex is basically a primary
cortex, whereas the primary sensory areas in humans account for a very small surface
in the cerebral cortex when compared to the associative and frontal areas that are more
extensive. Associative and frontal areas in humans are involved in many neurological dis-
orders, including ASD, attention deficit-hyperactive disorder, and dyslexia, among others.
Therefore, an evo-devo approach to neocortical evolution among species is fundamental to
understand not only the role of thyroid hormones and environmental thyroid disruptors on
evolution, development, and organization of the cerebral cortex in mammals but also their
role in neurological diseases associated to thyroid dysfunction.
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INTRODUCTION
Evolutionary developmental biology (evo-devo) studies the devel-
opmental processes of different organisms to determine the ances-
tral relationships between them and to discover how develop-
mental processes evolved. It addresses the origin and evolution
of embryonic development and the modifications of develop-
mental process that produced novel features (Wikipedia, accessed
August 2014). Evo-devo teaches us that some fundamental devel-
opmental processes are preserved by the evolution among species
(1). The evo-devo approach is not only becoming crucial for
the modern study of evolution but also it helps in the under-
standing of morphofunctional alterations in human psychiatric
diseases. For instance, autism spectrum disorders (ASD) show
abnormal function of cortical areas, such as the frontal or asso-
ciative neocortices that are minimally present in rodents (2, 3).
An approach to the etiologic factors of psychiatric diseases can
be inferred by the study of homologous genetic pathways that
lead to similar developmental processes in both humans and
other mammals. A second issue is that several psychiatric diseases,
including ASD, show a wide spectrum of different phenotypes,
which are the result of both genetic (nature) and environmental
(nurture) factors (4); including among the latter the interaction
of comorbid disorders such as hypothyroidism and hypothyrox-
inemia (5). We begin this review with a summary of thyroid
hormone synthesis, transport, and cell actions, which are regu-
lated by a very complex assembly of transporters, deiodinases,
receptors, and cofactors. As such, tissues have some control over
thyroid hormone action, independent of circulating levels of
thyroid hormones. We continue with the analysis of the role
of thyroid hormones at different phases of brain development
and maturation, focusing our attention on vulnerable periods.
These periods occur during gestation and lactation when genetic
and environmental factors, which include nutrients and chem-
ical contaminants, interfere with maternal and offspring thyroid
health. There is evidence that anatomical characteristics of autistic
brains represent defects in processes that occur early in devel-
opment, in the first half of gestation. Moreover, genomic stud-
ies have revealed a catalog of critical genes for these processes
that are regulated by thyroid hormones. Finally, recent studies
have reported that thyroid hormone deficiency might contribute
to increase the number of autism phenotypes, and that disor-
ders associated with hypothyroidism and hypothyroxinemia, such
as intellectual impairment, seizures, and anxiety, are comorbid
of ASD.
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THYROID FUNCTION DURING BRAIN DEVELOPMENT
Thyroid hormones (T4, thyroxine; and T3, 3,5,3′-triiodo-l-
thyronine) are synthesized in the thyroid gland and are transported
to different tissues and organs where they regulate growth, matu-
ration, and function in many organs and systems of vertebrates.
In particular, the mammalian central nervous system (CNS) is an
important target of thyroid hormones from fetus to adult. How-
ever, the maximal vulnerability of the CNS to thyroid hormone
imbalance occurs during the earliest stages of brain development
(6–15).
In target cells, thyroid hormones can exert their action at
three levels: nuclear and mitochondrial (genomic) and non-
genomic (16). Genomic actions include (1) thyroid hormone cell
membrane transport, (2) thyroid hormone metabolism (involv-
ing its activation/degradation), and (3) binding to nuclear thy-
roid hormone receptors (TRs, also known as THRs), which are
ligand-regulated transcription factors (17–25).
THYROID HORMONE CELL MEMBRANE TRANSPORT
Thyroid hormone cell membrane transport is mediated by four
families of transporters: the Na+/taurocholate cotransporting
polypeptide (NTCP), the organic anion transporting polypep-
tide (OATP), monocarboxylate transporter (MCT), and the het-
erodimeric amino acid transporter (HAT) (26). From these,
Oatp14, Mct8, Mct10, Lat1, and Lat2 have been found to be
expressed in the brain (20, 26–33).
THYROID HORMONE METABOLISM (ACTIVATION/DEGRADATION)
Three selenoproteins catalyzing the deiodination of T4 (thyrox-
ine) and T3 (the active form for the genomic action) have been
identified: type 1 (D1), type 2 (D2), and type 3 (D3) iodothyro-
nine deiodinases. Only D2 and D3 have been found expressed in
the CNS. D2 has been found in the astrocytes and tanycytes [spe-
cial ependymal cells, Ref. (34)] and mediates the local generation
of T3. D3 mediates the degradation of T3 to T2 (diiodothyro-
nine, 3,5-diiodo-l-thyronine) and T4 to rT3 (35–37). In addition
to deiodination, iodothyronines are also metabolized by conju-
gation of the phenolic hydroxyl group with sulfate or glucuronic
acid (38).
THYROID HORMONE NUCLEAR RECEPTORS
In the CNS, there are three nuclear TR isoforms with high-affinity
to T3: TRα1 (codified by the THRA gene), TRβ1, and TRβ2
(codified by the THRB gene) (17, 20, 39, 40). TRα1 is the most
ubiquitous; it has been detected in the rat brain by embryonic
day 12 (E12) and in the human brain by the 10th week of gesta-
tion (41–43), regulating the expression of genes involved in the
development and maturation of the brain (44), while TRβ1 is
mostly expressed in the adult. In addition, N-terminal truncated
TRα1 (also known as p43) can serve as a T3-dependent transcrip-
tion factor that initiates global mitochondrial transcription (16,
45, 46).
Recent studies have shown that thyroid hormone signaling is
more diverse and complex than initially concluded. For instance,
apart from the canonic role of thyroid hormones mentioned
above, novel THRs synthetic ligands might also modulate TRs
action, and intra and extracellular signals can affect cell sensitiv-
ity to T3 influencing TRs gene expression, TRs translation and its
transport into the nucleus, and the recruitment of co-activators/-
inhibitors (21, 24, 47). Furthermore, thyroid hormones can show
non-genomic actions by binding to cell surface or cytoplasmic
receptors and by interacting with other signaling pathways (16,
21, 48).
In rodents and humans, almost all T3 found in the fetal cere-
bral cortex is generated through local deiodination of circulating
maternal T4 (13, 49, 50). The fetal dependence on maternal T4
is due (i) to the late development of the fetal thyroid gland (in
rodents thyroid function begins by E17–18 and in humans by the
18–20 gestational week) and (ii) to the increased activity of D2
and D3 deiodinases in placenta and fetal tissues (13, 35, 51, 52).
As a consequence of the increased activity of deiodinases in the
fetus, serum T3 levels are maintained low and the local generation
of cerebral T3 from T4 is enhanced (13, 50). To respond to this
requirement, there is an estrogen-dependent increase of maternal
thyroid function that transiently induces an increase of (i) circu-
lating thyroxine-binding globulin, affecting the T4 extra-thyroidal
pool, and of (ii) human chorionic gonadotropin, transiently stim-
ulating thyrocytes (53). This increased maternal thyroid function
consequently needs increased iodine intake.
NUTRITIONAL AND ENVIRONMENTAL FACTORS AFFECTING
THYROID FUNCTION
Several factors can affect thyroid function during gestation and
early postnatal development, including genetic mutations, infec-
tions, nutrients, and environmental contaminants. Iodine defi-
ciency from inadequate alimentary habits is the most common
cause of maternal and fetal thyroid dysfunction (54–57). In addi-
tion, selenium (a component of deiodinases), iron (a component
of the prosthetic heme group associated to the thyroperoxidase),
and other micronutrients are required for an adequate life-long
thyroid function, especially during development and adolescence
(58). Moreover, environmental anti-thyroid contaminants are
acquiring increased importance (55, 59–67).
THYROID FUNCTION-DISRUPTING CHEMICALS FROM
ENVIRONMENTAL CONTAMINANTS
A thyroid function-disrupting chemical is an exogenous chemi-
cal, or mixture of chemicals, that can interfere with any aspect
of hormone action (67). The mechanisms of action of disrupting
chemicals on thyroid function are not fully understood; some may
reduce serum T4 without increasing serum TSH while others may
interfere with thyroid hormone action at sites other than the thy-
roid gland without altering serum TSH levels (21, 67). Howdeshell
(59) listed synthetic chemicals that interfere with thyroid hormone
synthesis, transport, and metabolism. Some are quite specific such
as perchlorate salts that block the sodium/iodide symporter (68),
but the majority affects several phases of thyroid hormone action.
Some thyroid disruptors are consumed in the diet (5, 63); for
instance, plant isoflavonoids such as genistein and daidzein from
soy inhibit thyroperoxidase that catalyzes iodination and thyroid
hormone biosynthesis; thiocyanate from cassava not only blocks
iodine uptake by thyroid and mammary glands but also inter-
feres with thyroid peroxidase. Organochlorides (including mostly
DDT and its derivative: p,p′-DDE, dichlorodiphenyl dichloroeth-
ylene; HCB, hexachlorobenzene; PBB, polybrominated biphenyls;
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and PCB, polychlorinated biphenyls) interfere with thyroid func-
tion acting upon iodine uptake, thyroid peroxidase action, thyroid
hormone binding proteins, and thyroid hormone metabolism,
resulting in a wide spectrum of thyroid-related syndromes (59,
69). The increased use of nanoparticles in several industrial,
consumer, and medical applications has revealed their unique
physico-chemical properties. However, in vitro and in vivo stud-
ies have shown that they may have toxic effects on the endocrine
system (70). It has been found that Ag-nanoparticles and cad-
mium telluride-quantum dots alone induced a reduction in the
expression TRβ (71).
IODINE DEFICIENCY DISORDERS AND
NEURODEVELOPMENTAL DAMAGE
As mentioned before, during gestation, the mother must produce
sufficient amounts of thyroid hormones (fundamentally T4) for
herself and her fetus. Iodine intake is the principal source of cir-
culating inorganic iodine; therefore, sufficient iodine is critical for
the thyroid gland to produce adequate amounts of thyroid hor-
mones (9, 13, 53, 57, 72–77). The fetus also depends on the mother
for its iodine supply, as does the neonatal thyroid during lactation
(78). To achieve this, expecting mothers need to double the recom-
mended normal daily intake of iodine for non-pregnant women
by 250–300µg/day (79).
Useful food strategies developed to increase iodine intake in
iodine-deficient areas include (i) use of iodinated salt in the house-
hold, (ii) incorporation of iodine to industrially elaborated foods
(i.e., bread, milk, and cheese), and (iii) dietary diversification
(i.e., consuming food from iodine-sufficient areas and seafood).
Despite these strategies, inadequate iodine intake actually affects
a large number of women during pregnancy and lactation, and
this situation currently persists even in countries classified as free
of iodine deficiency where iodized salt consumption has been
promoted for years (79–84).
Iodine deficiency is one of the most frequent causes world-
wide of preventable mental retardation in children (85). A wide
spectrum of iodine deficiency disorders has been described dur-
ing gestation and the early postnatal period (<3 years of age),
ranging from abortion, stillbirths, congenital anomalies, deafness,
cretinism, neurocognitive delay, epilepsy, schizophrenia, ASD, as
well as attention deficit hyperactive disorder (ADHD), among
others (3, 8, 63, 72, 86–94). In children, the severity of the neurode-
velopmental damage caused by iodine deficiency during gestation
depends on several factors: (i) the developmental period affected,
(ii) its severity, (iii) the deficiency of other nutrients such as sele-
nium and iron, and (iv) the interaction with thyroid function
disruptors (9, 10, 14, 57, 58). Epidemiological studies performed
in several countries have shown that hypothyroxinemia due to
mild iodine deficiency during gestation causes neurological alter-
ations, including low IQ in children (8, 87, 88, 95–99). As men-
tioned above, iodine deficiency in conjunction to the deficiency
of other nutrients and the interaction with thyroid function dis-
ruptors will cause a wide spectrum of syndromes associated to
thyroid pathologies. In countries with severe iodine and selenium
deficiencies, a high incidence of Kashin–Beck osteoarthropathy
associated with cretinism has been observed (100). The incidence
of myxedematous cretinism increases in countries where severe
iodine and selenium deficiency is associated with high intake of
thyroid disruptors found in foodstuffs such as cassava, which con-
tain thiocyanate (5, 101). The study of the alterations resulting
from nutritional deficiencies in combination with thyroid func-
tion disruptors should contribute to our understanding of the
multiple syndromes observed in thyroid diseases.
CRITICAL ISSUES OF CEREBRAL CORTEX DEVELOPMENT
For ethical reasons, the role of thyroid hormones on brain develop-
ment is currently studied using animal models, usually mice and
rats. However, although there are basic common developmental
principles regulating brain development between mammals, there
are also important differences. For instance, the understanding
of how different types of neocortex evolved depends on deter-
mining not only the numbers and types of cortical areas that
exist but also how the internal organization of those areas was
modified in the various lines of evolution, including modifica-
tions in columnar organization (102). Sexual dimorphism among
species also plays an important role, particularly in humans, while
in rodents little is known about sex differences between cere-
bral hemispheres (103). Changes in the organization and size
of neocortex also are reflected in the size of cortico-cortical
and subcortical projections, in turn affecting target areas (104).
Thus, increasing our evo-devo knowledge on neocortical evo-
lution among species (2) will help us to understand not only
the role of thyroid hormones and environmental thyroid dis-
ruptors on the development, organization, and evolution of the
cerebral cortex in mammals (105), but also their role in human
associated diseases. The evo-devo considers crucial for the evo-
lution that homologous developmental gene networks are shared
among species (1), and it emerges from the relationship between
developmental biology and evolution, which in turn are dynam-
ically coupled (106). For instance, basic gene networks involved
in symmetric divisions of ventricular neuroblasts during cere-
bral corticogenesis are common in rodents and humans, while
humans evolved by increasing the number of symmetrical divi-
sions, which results in an increased number of cortical columns
and therefore an increased cortical surface [see figure 2A by Rakic
(2)]. Apart from homology, convergence can also bring solu-
tions for common functional problems. However, little is known
on how functional needs have selected different functional net-
works to generate a similar function between different species,
such as the wings of birds and bats (1). Genetic (nature) and
environmental (nurture) factors cooperate along time, resulting
in differentiation (4). Psychiatric diseases, such as ASD, occur in
cerebral areas (e.g., frontal and associative) that are not present
in rodents; however, many homologous functional networks, like
those involved in radial migration, have been preserved. Fur-
thermore, ASD show a wide spectrum of different phenotypes,
resulting in different degrees of morphofunctional alterations and
in the concurrence of different comorbid disorders (107). Thy-
roid hormone deficiency increases comorbidity and the risk of
developing ASD (3). For instance, thyroid hormone deficiency
during neocorticogenesis results in abnormal development of
cortical gamma-aminobutyric acid (GABA)-ergic neurons, which
cause altered columnar function in the cerebral cortex and ASD
comorbid seizures (108).
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The cerebral cortex in all mammalian species, including
humans, differs from the development of other organs of the body
and even from the rest of the brain. It is a three-dimensional sheet
of layers, parallel to the pial surface, mostly composed of projec-
tion (or glutamatergic pyramidal) and local neuronal circuits (or
glutamatergic and GABAergic interneurons) organized in verti-
cal (or radial) columns that are stereotypically interconnected and
share extrinsic connectivity in order to achieve their functions
(109). During telencephalic corticogenesis in mammals, includ-
ing humans, layer I and subplate (deriving from the superficial
primordial plexiform layer) are the first cortical layers to appear
(110). Subsequently, young cortical neurons begin to migrate radi-
ally from the ventricular zone into the superficial cortical plate,
adjacent to layer I, following an “inside-out” gradient (111). While
in rodents, the neurogenesis of layer I is arrested when radial
migration begins, in primates neurogenesis continues during all
the periods of corticogenesis (112). Neurons migrate radially to the
increasingly distant cortex following the scaffolding of a transient
population of radial glial cells (113), in which many signaling path-
ways – such as reelin, metabolic functions, and gene expression
must be involved (114). This phase of corticogenesis is of capital
importance because an evo-devo approach of neocortical develop-
ment and evolution can be explained by the radial unit hypothesis
proposed by Rakic (115). As reported by Rakic (2) and mentioned
above, increased number of symmetrical divisions will increase the
number of functional columns, resulting in increased tangential
cortical surface, while that of asymmetrical ones will increase the
number of cells per column, resulting in increased cortical thick-
ness [see also figure 2A by Rakic (2)]. The final number of these
divisions will depend of apoptotic, anti-apoptotic, or inhibitory
factors, and will give rise to either the small lissencephalic cere-
brum of rodents or to the larger convoluted cerebrum of humans,
as well as to the emergence of new functional areas, such as the
prefrontal cortex and associative perisylvian areas (2). The graded
expression of transcription factors such as Emx2, Pax6, Coup-Tf1,
and Sp8 are implicated in the arealization of the neocortex (116,
117). Deletion or overexpression of these factors results in changes
in gene expression, contractions, and expansions in the sizes of
cortical fields, and altered patterns of connectivity from the dorsal
thalamus (117). Emx2 and Fgf genes share reciprocal functions in
regulating cortical patterning; in the frontal cortex, this is accom-
plished at least in part through controlling the levels of Erm, Er81,
Pea3, and Sp8 expression (118, 119). These results support the
protomap model (115, 120, 121) because neurons are commit-
ted to their areal position at the time of their last cell division
(the asymmetrical one) in the proliferative zones in the absence
of thalamic afferent inputs, although individual cortical areas may
be selectively changed in size during the course of evolution by
altered expression signals of their downstream transcription fac-
tor signaling mechanisms, as mentioned above (2). In addition,
changes in gene expression extrinsic to the neocortex in response
to physical stimuli in a particular environmental context might
play a crucial role in the formation of domains and areas in the
neocortex (117, 122, 123).
In rodents, radially migrating neurons comprise about 80%
of the total cortical neurons and will become glutamatergic
neurons. The remaining 20% of the cortical neurons migrate
tangentially (i.e., parallel to the pial surface) from the ganglionic
eminences to their target area and will become local circuit
neurons, mostly GABAergic neurons (124–126). In humans, dif-
ferently from rodents, a subset of neocortical GABAergic neu-
rons [Mash1-positive; a marker for precursors of glutamic acid
decarboxylase (GAD)-expressing cells] originates in the ventricu-
lar/subventricular zones of the dorsal telencephalon as a distinct
neuronal stem cell lineage [Ref. (127, 128); see figure 5 by Rakic
(2)]. The identification of the telencephalic origin of local circuit
neurons in cerebral cortex of mammals is of capital importance
to understand mechanisms operating during primate brain evolu-
tion (2, 129, 130) and the pathogenesis of congenital and acquired
neurological disorders, such as ASD, related to defects of separate
classes of local circuit neurons (131, 132).
In rats, the bulk of neocortical radial migration starts by
embryonic day 13 (E13), while the last cohort of cells leaves the
ventricular zone by E20 (133). During this process of radial and
horizontal migrations, the subplate neurons attract“waiting”affer-
ents from ipsilateral and contralateral cortical areas (including
associative and commissural connections), and subcortical con-
nections [including thalamic, nucleus basalis, and monoamine
connections (2), see also the figure 2B of this reference]. At the
end of this process, neurons and glial cells grow and differenti-
ate, including the loss of juvenile transient connections, to express
their mature phenotype, which also contributes to the radial and
tangential expansion of the cortex (134). In humans, neocortical
development occurs between the 6th and 24th week of gestation
(110, 135). The main waves of radial migration in the human neo-
cortex occur during the first half of gestation, with peaks at 11 and
14 weeks of gestational age (110, 135), and mostly before onset
of fetal thyroid hormone secretion by the 18th week of gestation
(136). This roughly corresponds to waves of cell migration studied
in rats (10), which also occur before onset of fetal thyroid hormone
secretion, by E17.5–18 (136). Despite the longer development and
maturation of the CNS in humans compared with rats, similarities
may be established when the onset of fetal thyroid gland secretion
is taken as the reference point. However, when comparing the
rodent lissencephalic and the primate convoluted mature neocor-
tex, the major differences are found in the tangential rather than
in the radial expansion [see figure 1 by Rakic (2)].
EXPERIMENTAL MODELS TO STUDY CORTICAL
ALTERATIONS CAUSED BY THYROID HORMONE DEFICIENCY
Several experimental models have been developed to study alter-
ations in the CNS caused by thyroid hormone deficiency. These
models can be grouped into (i) genetic mutants, (ii) surgically
induced hypothyroidism, (iii) metabolite deficient diets, and (iv)
thyroid function disruptor models.
Several genetic models were developed during the last decades
to study different forms of developmental and postnatal hypothy-
roidism, such as congenital hypothyroidism (137). Genetic models
can be classified into two main groups: (1) mutations affect-
ing thyroid gland development and function, and (2) mutations
affecting thyroid hormone sensitivity, which includes thyroid hor-
mone cell membrane transport, metabolism, and action (25).
The first group includes mutations of the TSH receptor (hyt−/−
mice) (138) and agenesis or functional impairment of thyrocytes
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(TTF1−/−, TTF2−/−, and Pax8−/−mice) (139). The second group
includes thyroid hormone transporters mutants such as Mct8−/y
(140, 141), Mct8−/− (142), and Lat2−/− (143). These mutant mice
have provided new data to understand thyroid hormone trans-
port in the cell membrane and clarified the physiopathology of
the Allan–Herndon–Dudley syndrome, which is caused by MCT8
defect (141, 144–146). Thyroid hormone metabolism in the brain
has been studied using different mutant mice affecting D2 and
D3 expression (Dio2−/−, Dio3−/−, and Dio2−/−Mct8−/y mice)
(147–149). Important genes associated to cortical development
are affected in Dio mutants. In particular, the neuronal genes
Gls2 (glutaminase 2), Nefh and Nefm (heavy and medium neu-
rofilament polypeptide), Sema7a (semaphorin 7A), Shh (sonic
hedgehog), Col6a1 and Col6a2 (type VI α1 and α2 collagen), as
well as Slc1a3 (glial high-affinity glutamate transporter) and Itga7
(integrin α7), among others, found in glial cells (148). Mutations
of the TR gene include TRα−/−, TRβ−/−, and TRα−/−β−/− mice,
as well as TRα and TRβ knock-in mutations (23, 150). Mutations
of TRβ gene are associated to the Refetoff syndrome (151, 152). A
classification of these mutations and their associated syndromes
of impaired sensitivity to thyroid hormone has been recently
published (25).
The most common models are based on the administration
of anti-thyroid drugs interfering either with the thyrocytes iodine
uptake by inhibiting the sodium/iodine symporter (e.g., potassium
perchlorate and thiocyanate) or with the iodination of thyroglob-
ulin by thionamide and thiourylene drugs such as propylthiouracil
(PTU) and methimazole (MMI) (153–155). In addition, PTU (and
less MMI) partially inhibits iodothyronine deiodinases affecting
the peripheral deiodination of T4 (154, 156). Anti-thyroid treat-
ments result in maternal, fetal, and neonate hypothyroidism of
greater or lesser severity (157). MMI treatment was also used
experimentally to induce mild and transient maternal hypothy-
roxinemia at the onset (E12) of fetal neocorticogenesis (158, 159).
Models for iodine deficiency during gestation include monkeys
(160), sheep (161), and rats (162, 163). These studies have shown
changes in the cerebellum with reduction in weight and cell num-
ber, and delayed maturation. The influence of iodine deficiency
on neocortical development has been studied in rats that are fed a
low iodine diet during pregnancy (163–166).
Alternatively, surgical thyroidectomy can be used to induce
hypothyroidism (167, 168), when performed in pregnant dams
it causes maternal but neither fetal nor neonate hypothyroidism.
Recently, late maternal hypothyroidism (LMH) during gestation
has been used as a model to study the role of maternal thyroid
hormones from the onset of fetal thyroid function (169).
ALTERATIONS IN CORTICAL DEVELOPMENT CAUSED BY
THYROID HORMONE DEFICIENCIES
GENES REGULATED BY THYROID HORMONES INVOLVED IN BRAIN
DEVELOPMENT
Fundamental genes involved in brain development are regulated
by thyroid hormones. The irreversibility and importance of dam-
age will depend on when, where, and how the alterations of gene
expression occur (10, 20). Early studies showed that maternal
thyroid hormones regulate gene expression in fetal development
modulating the expression of NSP and Oct-1 genes; T4 injections
produced rapid, transient, and selective effects on gene expression
in the fetal brain (170). Additional genes regulated by maternal
thyroid hormones included Nrgn (neurogranin, also known as
RC3), found to be significantly decreased (171), as well as reelin,
apolipoprotein E receptor 2 (ApoER2; a reelin receptor involved
in the migration young neocortical neurons), very-low-density
lipoprotein receptor (VLDLR; a reelin receptor that mediates the
stop signal), integrin genes, and genes involved in the downstream
phosphorylation of Dab1 (very-low-density lipoprotein receptor
1) (172, 173). cDNA microarray studies have shown a number
of genes to be transcriptionally or functionally modulated by T3;
most of these are involved in cell division, migration, growth, con-
nectivity, and function of neural cells. Using rat pituitary GC cell
line, Miller et al. (174) showed that 358 out of 4,400 genes were
regulated by T3; and, in a recent study, Morte et al. (44) found
552 out of 14,209 genes regulated by fetal and maternal thyroid
hormones at the end of gestation in rats. The function of some of
these genes is unknown but most of them are involved in the reg-
ulation of key pathways for the development of the cerebral cortex
in rodents and humans. Tables 1–6 list some of the most relevant
T3-regulated genes at the transcriptional level. Among those of
relevant importance for the development of cortical connections
are Nefh, Nefl, and Nefm (coding neurofilament proteins); Slit1,
Slit2, Nos1, Camk4, and Creb1 (involved in bifurcation and growth
of neural processes); Sema3B, Slit1, and Slit2 (guiding axons); and
Slc17a7 (coding vesicular glutamate transporter 1; VGluT1). T3
action on the regulation of the Camk4/Creb pathway and down-
stream targets (175) in neurons of the CNS is highly relevant since
Camk4 has not been found expressed in glial cells (169, 176, 177).
Camk4 is directly induced by T3 at the transcriptional level (44),
and phosphorylates Creb. Many of the genes under thyroid hor-
mone control contain Creb binding sites in their promoter region
(149). On the other hand, Camk4 regulates the transcriptional
activity of the TR, which might be due to direct phosphoryla-
tion of co-activators or by changing the equilibrium between the
co-activators and the silencing mediator for retinoid and thyroid
hormone receptors (SMRT) (178, 179). Camk4/Creb pathway and
downstream targets are involved in processes such as neurogene-
sis, biosynthesis, and assembly of cytoskeleton, cell movement and
migration, neurite development and maturation, synaptic plas-
ticity, and neurotransmission (44, 180). In humans, Camk4/Creb
pathway is involved in psychiatric disorders (181–183). There is
a strong evidence for the action of Camk4/Creb pathway in the
expression of FMR1 gene, encoding fragile X mental retardation
protein (FMRP) (184, 185). Lack of FMRP causes fragile X syn-
drome, which is the most common cause of inherited mental
retardation and ASD (186, 187). In addition, brain-derived neu-
rotrophic factor (BDNF)/Erk signaling modulates FMRP function,
affecting neuronal proliferation and differentiation in the cerebral
cortex [Ref. (188, 189); Table 5].
ALTERED NEUROGENESIS AND MIGRATION DURING CORTICOGENESIS
Indirect observations based on the cell density estimates and brain
size measurements suggested a reduced number of cells in the neo-
cortex of developmentally hypothyroid rats (190). Neural progen-
itors in the ventricular zone of mouse telencephalon express TRα1,
Mct8 transporters, and deiodinases, and maternal hypothyroidism
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Table 1 | SignificantT3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in cell division and
differentiation: relationship with ASD.
Symbola Protein Process Alteration/disease
ADCYAP1R1 Adenylate cyclase-activating polypeptide
receptor (PAC1)
Signaling pathway Decreased second messenger
CASP3 Caspase 3 Protease Apoptosis. Alzheimer’s disease
CCND1 G1/S-specific cyclin-D1 Interact with tumor suppressor protein Rb Abnormal cell cycle G1/S transition
CNN1 Calporin (actin binding protein; fimbrin type) Actin associated protein Abnormal cohesion between parental
centrioles
CREB1 cAMP-responsive element binding protein 1 Transcription factor Altered development. ASD
CREM cAMP-responsive element modulator Transcription factor modulating CREB Altered development. ASD
CTNNB1 β-catenin Regulates the coordination of cell–cell
adhesion and gene transcription
Altered asymmetric cell division,
epithelial-to-mesenchymal transition. ASD
DYRK1A Dual specificity tyrosine-phosphorylation-
regulated kinase 1A
Nuclear signaling Abnormal cell proliferation and may be
involved in brain development. ASD
GNB1L Guanine nucleotide-binding protein subunit
β-like protein 1
Six WD40 repeat-containing protein Abnormal cell cycle progression.
Schizophrenia. ASD
FLT1 Vascular endothelial growth factor receptor 1 Protein kinase Abnormal control of cell proliferation and
differentiation. ASD
HIST1H1T Histone H1t Compaction of chromatin Abnormal cell cycle and differentiation
HSD11B2 Corticosteroid 11-β-dehydrogenase isozyme 2 Hydrolysis of cortisol Cortisol induction of growth-inhibition and/or
pro-apoptosis embryonic development
MAPK1 Mitogen-activated protein kinase 1 (ERK2) CREB1 phosphorylation signaling pathway ASD
RGS3 Regulator of G-protein signaling 3 Ephrin-B signaling pathway Early cell cycle exit and precocious
differentiation
aBold shows T3-regulated genes that have been found to be abnormally expressed in autistic humans. Other genes found in autistic humans not regulated by T3 at
the transcriptional level have not been included.
reduces the cell cycle length of these progenitors (191). Since in
hypothyroid fetuses the bulk of the neocortical BrdU-labeling
occurs between E12 and E19 as in control rats (192), the data by
Mohan et al. (191) clearly indicated that the total neuronal progen-
itor number is reduced in the cerebral cortex. Using 3H-thymidine
labeling, a significant reduction was observed in cell acquisition in
the granular layer of the hippocampal dentate gyrus in postna-
tal PTU treated pups (193). These authors also observed that the
radial migration of newly generated hippocampal granular cells
could be arrested and that the decreased number of labeled cells
in the granular layer might result from deficient migration rather
that decreased mitotic activity. Several genes involved in cell cycle
regulation during neurogenesis have been found to be regulated
by T3 [Ref. (44); Table 1]. CCND1 (G1/S-specific cyclin-D1) is
downregulated by T3, resulting in an abnormal cell cycle pro-
gression (194). In addition, T3-regulated regulator of G-protein
signaling 3 (RGS3) plays a key role in ephrin-B signaling, control-
ling cell cycle exit, and differentiation of neural progenitors (195),
and dual specificity tyrosine-phosphorylation-regulated kinase 1A
(DYRK1A) is involved in the control of cell proliferation in ASD,
causing arrested brain growth (196). Other T3-regulated genes
such as CNN1 (calporin), which is an actin associated protein, also
exerts a control of cell cycle during neurogenesis (197). Recently, it
has been found that developmental mild and severe hypothyrox-
inemia and MMI-induced hypothyroidism alters Shh signaling
pathway in the cerebellar granule cell precursors, resulting in
downregulation of D1 and D2 cyclins, of E2F1 expression, and in
reduced cell proliferation (198). However, it still remains unclear to
what extent thyroid hormones affect symmetrical and asymmetri-
cal divisions of neocortical progenitor cells. Studies on the mouse
barrel cortex (192) suggest that both symmetrical and asymmetri-
cal divisions are altered in hypothyroid rats, because the tangential
area of the posteromedial barrel subfield stained with cytochrome
oxidase (resulting from symmetrical divisions) and the thickness
of the barrel cortex (resulting from asymmetrical divisions) are
reduced by 27 (Figures 1A–D) and 12.5% (Figure 1E), respec-
tively, in hypothyroid rats. Nevertheless, from these data we could
argue that most likely the symmetrical divisions are compara-
tively more affected in hypothyroid rats. The reduced thickness of
the cortex in hypothyroid rats could be explained by a reduction
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Table 2 | SignificantT3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in cytoskeleton organization
and cell migration: relationship with ASD.
Symbola Protein Process Alteration/disease
APOER2 Apolipoprotein E receptor 2 (Lrp8) Reelin signaling pathway Alzheimer, major depressive disorder
CALR Calreticulin Endoplasmic reticulum calcium-binding
protein
Abnormal calcium storage in the
hippocampus. Alzheimer’s disease
CREB1 cAMP-responsive element binding protein 1 Transcription factor Altered development. ASD
CREM cAMP-responsive element modulator Transcription factor modulating CREB Altered development. ASD
CTSS Cathepsin S Protease Abnormal microglial function
DAB1 Disabled-1 Reelin signaling pathway Abnormal migration. Alzheimer’s
disease, temporal lobe epilepsy. ASD
DYNLL1 Dynein light chain 1, cytoplasmic Microtubule associated protein Abnormal intracellular transport and
motility
FMOD Fibromodulin Proteoglycan that sequesters TGF-β into
the extracellular matrix
Abnormal regulation of proliferation
and differentiation of hippocampal
granule neurons
FN1 Fibronectin Extracellular matrix protein Abnormal cell adhesion, growth,
migration, and differentiation. ASD
GNAS G-protein α subunit (Gs-α) Signaling pathway ASD. ADHD
HSPD1 Chaperonin (HSP60) Chaperone Prevent traumatic brain injury
MAPK1 Mitogen-activated protein kinase 1 (ERK2) CREB phosphorylation signaling pathway ASD
NEFH , NEFM, NEFL Neurofilament protein (heavy, medium, and
light)
Intermediate filaments Abnormal neuronal cytoskeleton.
ASD
NOV Nephroblastoma overexpressed Extracellular matrix protein that binds to
integrin receptors
Abnormal cell adhesion, migration,
proliferation, differentiation,
and survival
OPCML Opioid-binding protein/cell adhesion
molecule
Cell adhesion molecule Abnormal proliferation and growth of
cortical astrocytes
PAFAH1B1 Platelet-activating factor acetylhydrolase IB
subunit α (Lis1)
Interact with dynein and VLDLR Lissencephaly. ASD
RELN Reelin Extracellular matrix protein Abnormal migration. Alzheimer’s
disease, temporal lobe epilepsy. ASD
SERPINH1 Heat shock protein 47 Chaperone Abnormal collagen binding. ASD
SLIT1, SLIT2 Slit homolog 1 and 2 proteins Extracellular matrix protein.
Chemorepulsive signal
Abnormal axon guidance. Abnormal
angiogenesis
TGFB2 Transforming growth factor-β 2 Extracellular matrix protein Abnormal regulation of proliferation
and differentiation of hippocampal
granule neurons
TPM1 Tropomyosin α-1 chain Actin associated protein Abnormal neuronal cytoskeleton
VLDLR Very-low-density-lipoprotein receptor Reelin signaling pathway Abnormal migration. Alzheimer’s
disease, temporal lobe epilepsy. ASD
aBold shows T3-regulated genes that have been found to be abnormally expressed in autistic humans. Other genes found in autistic humans not regulated by T3 at
the transcriptional level have not been included.
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Table 3 | SignificantT3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in neurite growth, guidance,
branching, and maturation: relationship with ASD.
Symbola Protein Process Alteration/disease
ANK3 Ankyrin-3 Cytosol protein that interacts with
voltage-gated sodium channels and
cytoskeletal proteins
Abnormal clustering of voltage-gated sodium
channels at the axon hillock and node of Ranvier
abnormal action potential firing. ASD
ARX Aristaless-related homeobox Transcription factor X-linked intellectual disability, epilepsy, lissencephaly,
agenesis of the corpus callosum. ASD
BDNF Brain-derived neurotrophic factor Extracellular signal Abnormal synaptic structure, function, and plasticity.
Fragile X syndrome. ASD
CAMK4 Calcium/calmodulin-dependent protein
kinase type IV
CREB phosphorylation signaling
pathway
ASD
CHN1 Chimerin 1 (GTPase-activating protein) Signal transduction Abnormal axon pruning
CNTN4 Contactin-4 Cell adhesion molecule Abnormal connectivity in the developing nervous
system. ASD
CREB1 cAMP-responsive element binding
protein 1
Transcription factor Altered development. ASD
CREM cAMP-responsive element modulator Transcription factor modulating CREB Altered development. ASD
FLT1 Vascular endothelial growth factor
receptor 1
Protein kinase. Signal transduction Abnormal control of cell proliferation and
differentiation. ASD
FN1 Fibronectin Extracellular matrix protein Abnormal cell adhesion, growth, migration, and
differentiation. ASD
HAP1 Huntingtin-associated protein 1 Interacts with huntingtin and
cytoskeletal proteins
Abnormal vesicular trafficking and organelle transport
KLF9 Kruppel-like factor 9 Transcription factor Altered development of neurons
MAPK1 Mitogen-activated protein kinase 1
(ERK2)
CREB phosphorylation signaling
pathway
ASD
NEFH , NEFM,
NEFL
Neurofilament protein (heavy, medium,
and light chains)
Intermediate filaments Abnormal neuronal cytoskeleton. ASD
NOS1 Nitric oxide synthase 1 Neurotransmitter, signaling pathway Abnormal signaling pathway. Neuroglial
inflammation. ASD
PLXNA2,3 Plexin-A2 Semaphorin co-receptor Abnormal axon guidance. Schizophrenia, anxiety
SEMA3B Semaphorin-3B Signal transduction Abnormal axon guidance
SLIT1, SLIT2 Slit homolog 1 and 2 proteins Extracellular matrix protein.
Chemorepulsive signal
Abnormal axon guidance. Abnormal angiogenesis
TGFB2 Transforming growth factor-β 2 Extracellular signaling protein Abnormal regulation of proliferation and
differentiation of hippocampal granule neurons
aBold shows T3-regulated genes that have been found to be abnormally expressed in autistic humans. Other genes found in autistic humans not regulated by T3 at
the transcriptional level have not been included.
of the columnar neuropile more than by a reduction in the cel-
lular components of the columns. T3-regulated CASP3 (caspase
3) and CTNNB1 (β-catenin) genes are crucial for cerebral cortex
expansion (Table 1). Experimental studies using caspase 3 and 9
KO mice (lacking apoptotic signals) (2, 199) and transgenic mice
expressing β-catenin (which increases the number of precursor
cells) lead to an abnormally convoluted mouse cortex (200). Cas-
pase 3 pathway is downregulated in the cerebral and cerebellar
cortices of hypothyroxinemic and hypothyroid rats (201, 202),
while β-catenin is T3-downregulated in rat pituitary cultured cells
(174). These data show that thyroid hormone deficiency alters the
tangential and radial organization of the cortex and might have
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Table 4 | SignificantT3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in synaptogenesis and
plasticity: relationship with ASD.
Symbola Protein Process Alteration/disease
ANXA6 Annexin A6 Calcium-binding protein Abnormal vesicle aggregation and fusion in the
hippocampal neuron’s axon initial segment
ATP2B2 Ca(2+)-ATPase Plasma membrane calcium-ATPase Abnormal translocation of calcium to the endoplasmic
reticulum in hippocampal neurons. ASD
BDNF Brain-derived neurotrophic factor Synaptic structure, function, and
plasticity. fragile X syndrome autism
Abnormal synaptic structure, function, and plasticity.
Fragile X syndrome. ASD
CAMK4 Calcium/calmodulin-dependent protein
kinase type IV
CREB phosphorylation signaling
pathway
ASD
CNTN4 Contactin-4 Cell adhesion molecule Abnormal connectivity in the developing nervous
system. ASD
CREB1 cAMP-responsive element binding
protein 1
Transcription factor Altered development. ASD
CREM cAMP-responsive element modulator Transcription factor modulating CREB Altered development. ASD
EXOC7 Exocyst complex component 7 Rho3 signaling Abnormal cell polarity, regulation of actin polarity and
transport of exocytic vesicles
HAP1 Huntingtin-associated protein 1 Interacts with huntingtin and
cytoskeletal proteins
Abnormal vesicular trafficking and organelle transport
HRH3 Histamine H3 receptors Signal transduction Abnormal presynaptic inhibition of neurotransmitter
release
MAPK1 Mitogen-activated protein kinase 1
(ERK2)
CREB phosphorylation signaling
pathway
ASD
NR4A1 Nuclear receptor related 1 protein
(NURR77)
Transcription factor Abnormal synaptic plasticity in the hippocampus.
Altered long-term potentiation. Schizophrenia
NRGN Neurogranin Calmodulin-binding protein.
Component of postsynaptic density
Abnormal synaptic plasticity and long-term
potentiation. Schizophrenia. ASD
PAFAH1B1 Platelet-activating factor
acetylhydrolase IB subunit α (Lis1)
Interacts with dynein and VLDLR Lissencephaly. ASD
PICALM Phosphatidylinositol binding clathrin
assembly protein
Coated vesicles Abnormal coated vesicles. Alzheimer’s disease
SLIT1, SLIT2 Slit homolog 1 and 2 proteins Extracellular matrix protein.
Chemorepulsive signal
Abnormal axon guidance. Abnormal angiogenesis
SNAP23 Synaptosomal-associated protein 23 SNARE associated protein Abnormal exocitosis
SNX16 Sorting nexin 16 Membrane associated protein Protein sorting
SQSTM1 Sequestosome-1 Ubiquitin binding protein Abnormal regulation of the nuclear factor kappa-B
(NF-κB) signaling pathway
SYT2 Synaptotagmin-2 Synaptic vesicles docking Abnormal exocitosis
SYTL5 Synaptotagmin-like protein 5 Synaptic vesicles docking. Marker for
parvalbumin immunoreactive buttons
Abnormal exocitosis
TGFB2 Transforming growth factor-β 2 Extracellular signaling protein Abnormal regulation of proliferation and differentiation
of hippocampal granule neurons
VAMP4 Vesicle-associated membrane protein 4
(synaptobrevin)
Synaptic vesicles docking Abnormal exocitosis
aBold shows T3-regulated genes that have been found to be abnormally expressed in autistic humans. Other genes found in autistic humans not regulated by T3 at
the transcriptional level have not been included.
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Table 5 | SignificantT3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in neurotransmission:
relationship with ASD.
Symbola Protein Process Alteration/disease
ADCYAP1R1 Adenylate cyclase-activating polypeptide
receptor (PAC1)
Signaling pathway Decreased second messenger
CACNG8 Calcium channel, voltage-dependent, γ
subunit 8
Transmembrane AMPA receptor
regulatory protein (TARP)
Altered long-term potentiation
CAMK4 Calcium/calmodulin-dependent protein
kinase type IV
CREB phosphorylation signaling pathway ASD
CREB1 cAMP-responsive element binding protein 1 Transcription factor Altered development. ASD
CREM cAMP-responsive element modulator Transcription factor modulating CREB Altered development. ASD
HAP1 Huntingtin-associated protein 1 Interacts with huntingtin and cytoskeletal
proteins
Abnormal vesicular trafficking and organelle
transport
HOMER1 Homer protein homolog 1 Major component of postsynaptic density Abnormal synaptic plasticity and long-term
potentiation. ASD
HRH3 Histamine H3 receptors Signal transduction Abnormal presynaptic inhibition of
neurotransmitter release
KCNC1 Potassium voltage-gated channel subfamily C
member 1
Membrane channel Abnormal repolarization of cortical
interneurons
KCNJ10 ATP-sensitive inward rectifier potassium
channel 10
Membrane channel Abnormal repolarization. Epilepsy, ataxia,
and deafness. ASD
KCNK2 Potassium channel subfamily K member 2
(TREK1)
Membrane channel Abnormal neuroprotection against epilepsy
and brain and spinal cord ischemia
KCNS2 Potassium voltage-gated channel subfamily S
member 2
Membrane channel Abnormal repolarization
KCNT2 Potassium channel subfamily T, member 2 Membrane channel Abnormal repolarization epilepsy, Alzheimer
disease
MAPK1 Mitogen-activated protein kinase 1 (ERK2) CREB phosphorylation signaling pathway ASD
NRGN Neurogranin Calmodulin-binding protein. component of
postsynaptic density
Abnormal synaptic plasticity and long-term
potentiation. Schizophrenia. ASD
NTS Neurotensin Neuropeptide Abnormal modulation of dopamine signaling.
ASD
PACSIN2 Protein kinase C and casein kinase substrate
in neurons protein 2
Binding to endocytic proteins Arrested endocytosis
PAFAH1B1 Platelet-activating factor acetylhydrolase IB
subunit α (Lis1)
Interacts with dynein and VLDLR Abnormal signaling. Lissencephaly. ASD
SLC17A7 Vesicular glutamate transporter 1 (VGLUT1) Synaptic vesicle membrane protein Abnormal neurotransmission
neuropsychiatric disorders. ADHD, and
schizophrenia. ASD
aBold shows T3-regulated genes that have been found to be abnormally expressed in autistic humans. Other genes found in autistic humans not regulated by T3 at
the transcriptional level have not been included.
contributed in the evolutionary elaboration of radial columns,
modulating both cortical surface and thickness.
Altered T3-regulated opioid-binding protein/cell adhesion
molecule (OPCML; also known as OBCAM) expression affects
radial glia function and its transdifferentiation to astrocytes
[Ref. (203); Table 2]. In agreement, impaired maturation of
radial glia was observed in the hippocampus of pups born to
chronic hypothyroxinemic rats (163) and in the neocortex of
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Table 6 | SignificantT3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in memory and behavior:
relationship with ASD.
Symbola Protein Process Alteration/disease
ADCY8 Adenylate cyclase type 8 G-protein associated enzyme Abnormal cAMP signaling
ADRBK2 β-adrenergic receptor kinase 2 (GRK3) G-protein-coupled receptor kinase 3 Abnormal dopamine metabolism.
Schizophrenia and bipolar disorder
CALB1 Calbindin-D28k Calcium-binding protein Abnormal synaptic plasticity and long-term
potentiation. ASD
CAMK4 Calcium/calmodulin-dependent protein
kinase type IV
CREB phosphorylation signaling pathway ASD
CREB1 cAMP-responsive element binding protein 1 Transcription factor Altered development. ASD
CREM cAMP-responsive element modulator Transcription factor modulating CREB Altered development. ASD
DBP D site of albumin promoter (albumin D-box)
binding protein
Transcription factor Abnormal spatial learning and enhanced
susceptibility to kainate-induced seizures.
Epilepsy, schizophrenia, and bipolar disorder
GRK5 G-protein-coupled receptor kinase 5 Signal transduction Memory impairment. Alzheimer’s disease
HOMER1 Homer protein homolog 1 Major component of postsynaptic density Abnormal synaptic plasticity and long-term
potentiation. ASD
HTR7 5-HT7 receptor Neuroreceptor Abnormal learning and memory.
Neuropsychiatric disorders. ASD
MAPK1 Mitogen-activated protein kinase 1 (ERK2) CREB phosphorylation signaling pathway ASD
NOS1 Nitric oxide synthase 1 Neurotransmitter, signaling pathway Abnormal signaling pathway. ASD
NR4A1 Nuclear receptor related 1 protein (NURR77) Transcription factor Abnormal synaptic plasticity in the
hippocampus. Altered long-term
potentiation. Schizophrenia
NTS Neurotensin Neuropeptide Abnormal modulation of dopamine signaling.
ASD
PVALB Parvalbumin Calcium-binding protein Alzheimer’s disease and nervous system
disorders. ASD
aBold shows T3-regulated genes that have been found to be abnormally expressed in autistic humans. Other genes found in autistic humans not regulated by T3 at
the transcriptional level have not been included.
developmentally hypothyroid pups (204). Abnormal radial migra-
tion in the neocortex of developmentally hypothyroid rats was
first described in the auditory cortex by combining BrdU and
tracer labeling (205). As a result, the radial positioning of migrat-
ing neurons was altered, including abnormally located heterotopic
neurons in the subcortical white matter (192, 205) (Figure 2C)
and corpus callosum (206). Also, altered neuronal migration in
the neocortex and hippocampus has been confirmed in hypothy-
roxinemic rats (158, 159, 164) (Figures 2A–C). Apart from TRs,
other nuclear receptors are involved in radial glia maturation and
radial migration in the neocortex such as the liver X receptor β
(LXRβ) that also regulates the expression of ApoER2 receptor
(207). LXRβ−/− mice showed altered cortical migration of later-
born neurons (208) and delayed transdifferentiation of radial glial
cells into astrocytes (209). Interestingly, LXRs bind to the same
response element on DNA as TRs and sometimes regulate the
same genes (150, 210). In fact, it has been shown recently that TRα
compensates for the lack of LXRβ in cortical development, and a
reciprocal compensatory action can also be hypothesized (207).
Heterotopic cells in the external granular layer of the cerebellar
cortex have also been observed (212), as well as in Mct8−/y mice
(213). The stunted migration of cerebellar cells found in previ-
ous studies (6, 214, 215) and in TRα1 mutant mice (212, 213)
suggests that thyroid hormones interfere with different mecha-
nisms involved in the migration of cortical and cerebellar neurons.
Cortical neurons retain most of their migratory capacity as can
be observed either in studies combining BrdU and tracer label-
ing (205) or using organotypic cultures (Figure 2D) (159). In
the latter, it was found that cells from transient hypothyroid
medial ganglionic eminence explants migrate as well as cells from
control explants when they were placed on normal host cortex;
and reversely, both control and transient hypothyroid median
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FIGURE 1 | Reduced development of cortical maps in developmental
hypothyroidism. (A) Cartoon showing the posteromedial barrel subfield of
the primary somatosensory cortex in the brain of a rat. Note the
correspondence between mysticial vibrises and the barrels of the
posteromedial barrel subfield. (B) Brain dorsal views at P40 of control (C)
and MMI pups. (C) Computer reconstruction from photomicrographs of
serial tangential sections through layer IV, showing cytochrome oxidase
labeling in the barrel cortex of normal and hypothyroid rats. Note the
reduced tangential extension of the cytochrome oxidase labeling in
hypothyroid with respect to normal rats. (D) Area measurements in normal
and hypothyroid rats. The dorsal view brain area was, on average, 24%
smaller in hypothyroid rats (upper). A similar reduction (on average, 27%)
was observed in the PMBSF tangential area (lower). (E) Photomicrographs
of cresyl violet stained coronal sections showing the cytoarchitecture of the
barrel cortex of the primary somatosensory cortex at P40 in control (C) and
transient MMI treated pups (MMI treatment begun at E12 and finished at
E15). Borders between layers (horizontal lines) are clear-cut in C whereas
they are more blurred in MMI12 pups. In layer IV of C and dMMI pups,
barrels (arrow) are normal and well-defined and demarcated by septae
(arrowheads). In contrast, barrels in layer IV of MMI1 pups are not seen. In
developmentally hypothyroid pups there is a 10–15% reduction in the
cortical thickness of MMI pups compared to controls. (A) Modified from
Berbel and Morreale de Escobar (57). (C,D) Modified from Berbel et al.
(192). (E) Modified from Ausó et al. (158).
ganglionic eminence cells showed altered latero-medial migration
when placed on transient hypothyroid host cortex, which suggests
that in the transient hypothyroid cortex the expression of chemo-
attractive/-repulsive/-stop signals and/or of their receptors [see
review in Ref. (126)] is altered. In fact, some of them, such as Slit1,
Slit2, and Sema3B, are regulated by thyroid hormones [Ref. (44);
Table 2].
ABNORMAL CORTICAL CYTOARCHITECTURE AND CONNECTIVITY
Blurred neocortical layering can be assessed in the rodent
somatosensory barrel cortex owing to the characteristic cytoarchi-
tecture of layer IV (192, 216). The parvalbumin immunostaining
pattern in hypothyroid rats is severely altered in the neocortex
(211, 217, 218) (Figure 2E) and hippocampus (217, 219). Inter-
estingly, parvalbumin positive neurons (i.e., GABAergic chandelier
and basket neurons that migrate tangentially from the medial gan-
glionic eminence) also exhibit altered tangential migration in the
transient hypothyroxinemic cortex (159). The decreased chande-
lier and basket parvalbumin immunoreactive terminals in the neo-
cortex (211, 217) and hippocampus (217) will affect the inhibitory
control of glutamatergic neurons (220) and might explain the
high incidence of audiogenic seizures reported in hypothyroid
rats (221) and in the pups of mild and transient hypothyroxinemic
pregnant rats (158) (Figure 2F).
Early postnatal hypothyroidism affects the growth of dendrites
in both the cerebral (193, 222) and cerebellar (223) cortices. Qual-
itative and quantitative ultrastructural studies of the cerebellar
molecular layer in rats show that the retardation in synaptogenesis
between Purkinje cell dendritic spines and parallel fibers was asso-
ciated to hypoplasia of Purkinje cell dendrites and to the retarded
development of parallel fibers (223). In the neocortex, it has been
found that β-catenin is downexpressed in the dentate gyrus of
postnatal hypothyroid rats (165) and the Wnt/β-catenin signal-
ing plays a crucial role for the growth and branching of dendrites
(224). Developmental hypothyroidism affects maturation of com-
missural axons (225–228). In adult hypothyroid rats, the number
of myelinated axons was 76 and 66%, respectively, in both the ante-
rior commissure and the corpus callosum compared to controls
(228); also, the maturation of cytoskeletal components was altered
(226, 229) and the growth of axon caliber was arrested (225, 228).
Development and maturation of oligodendrocytes in the forebrain
commissures of hypothyroid rats may also be affected. In fact,
cortical expression of myelin-associated glycoprotein, proteolipid
protein, and myelin basic protein in oligodendrocytes is strongly
reduced (230).
Callosal-projecting neurons were found mostly in infra-
granular layers of the auditory cortex of developing (205) and adult
hypothyroid rats (216). In addition to altered radial distribution,
the total number of callosal neurons was increased in auditory
(216) and visual (226) cortices, and in cortical projecting neurons
such as in the occipito-spinal connections (231), revealing mainte-
nance of exuberant projections in hypothyroid rats. Interestingly,
in the hypothyroid MMI model, the heterotopic white matter neu-
rons, in particular, the early BrdU-labeled ones normally destined
for the subplate, could provide a target to the transient callosal
axons as they might in normal development (134, 232).
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FIGURE 2 | Abnormal neuronal radial and tangential migration, inhibitory
local circuits and increased audiogenic seizures in developmental
hypothyroidism and hypothyroxinemia. (A,B) Photomicrographs of
NeuN-immunostained coronal sections of the primary somatosensory cortex
(A) and hippocampal CA1 (B) in LID+KI (rats fed low iodine diet plus
approximately 10µg iodine per day, during gestation and postnatally) and LID
(rats fed low iodine diet) progeny at P40.The number of NeuN-labeled neurons
increases both in subcortical white matter [wm (A)] and in strata oriens (or)
and alveus [al (B)] of hippocampal CA1 of LID pups as compared with LID+KI
pups. (C) GFAP- and CNP-positive astrocytes (left panel) and oligodendrocytes
(right panel), respectively (arrowheads), and BrdU-positive nuclei (arrows) are
shown in layer V of C and LID pups. LID rats received single BrdU injections at
E14, E15, and E16. Note that both GFAP-positive astrocytes and CNP-positive
oligodendrocytes are BrdU-negative. (D) Low power fluorescent photo-
micrograph collage illustrating the tangential distribution of GFP-MGE control
migrating neurons (control explant, CE) in wild control flat cortical mounts at
E15 (control cortex, CCx; left), and GFP-MGE hypothyroxinemic migrating
neurons (3dMMI10) in hypothyroxinemic flat cortical mounts (3dMMI10Cx;
right). Note that migrating neurons toward the medial (M) region in the
hypothyroxinemic cortical mount (right) expand less than those migrating in
the control cortical mount (left). 3dMMI10 rats received MMI treatment
(Continued)
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FIGURE 2 | Continued
from E10 to E12. (E) Photomicrographs through layer V of the auditory
cortex immunostained for parvalbumin in normal (C) and hypothyroid
(MMI treatment from E14 onward) rats. In normal rats, immunoreactive
cells, processes and perisomatic puncta can be seen. In MMI rats,
immunoreactive cells, processes and perisomatic puncta can also be
seen but they are less prominent than in normal rats. (F) Responses of C
and 3dMMI12 (MMI treatment from E12 to E15) pups to an acoustic
stimulus. Histograms on the left correspond to the proportion (median
with 25th and 75th percentiles) of pups responding with wild runs and
with wild runs followed by a seizure, respectively. Graphs on the right
represent the cumulative frequency of pups from the same groups that
respond with wild runs alone or followed by a seizure, respectively, at the
intervals after onset of the stimulus that are shown in the abscissa. (*)
Indicates a statistically significant difference compared with control.
(A–C) Modified from Lavado-Autric et al. (164). (D) Modified from Cuevas
et al. (159). (E) Modified from Berbel et al. (211). (F) Modified from Ausó
et al. (158).
DELAYED CORTICAL MATURATION
There is a strong evidence that subplate neurons play an important
role in thalamocortical axon path finding (233, 234). Subplate neu-
rons may fire action potentials (235) and they are necessary for the
establishment of ocular dominance and orientation columns (236)
and for the maturation of inhibitory circuits in layer IV (237). The
dynamic integration of subplate neurons into the rodent neocortex
during postnatal development may play a key role in establishing
the cytoarchitectonic pattern in layer IV and to refine layer IV
circuitry (238). Recent studies have shown that subplate neurons
remain expressing Camk4 in adult hypothyroid rats, while in nor-
mal rats, Camk4 is not longer expressed in subplate neurons by
P10 [Ref. (239); Figures 3A–C]. Subplate and white matter abnor-
malities have been related to the pathogenesis of various brain
developmental disorders other than ASD, such as periventricu-
lar leukomalacia, schizophrenia, and cerebral palsy (240–244). A
recent study shows the crucial importance of the identification of
subplate cell subpopulations, which may have very different roles
in various pathologies such as ASD and schizophrenia (245).
Serotonin (5-HT) immunostaining is a good transient marker
for thalamic afferents in the visual, auditory, and somatosen-
sory areas of rats during the first postnatal days. In the barrel
cortex of hypothyroid rats, immunolabeling persisted for 5 days
until P16–17 [Ref. (246); Figure 3D]. A similar protracted expres-
sion of 5-HT transporter (5-HTT) occurred in the ventro-basal
thalamic nucleus and cerebral cortex (246). Reduced 5-HT lev-
els during barrel formation delay the differentiation of layers II,
III (247, 248) and reduce the tangential extent of thalamocortical
arbors within barrels (249). Thus, prolonged 5-HTT expression
in the hypothyroid ventro-basal thalamic nucleus should decrease
the concentrations of 5-HT in the extracellular space of sensory
cortices, affecting their organization and differentiation.
In the barrel cortex of adult hypothyroid rats, the radial distri-
bution of thalamic afferents, anterogradely labeled with dextran–
biotin amine and DiI, was reduced compared to normal rats [Ref.
(246); Figure 3G]. By single reconstructions of terminal arbors
(Figure 3H), these authors showed a reduction of the number
of axonal branches reaching layers II–IV, and a 49% reduction
in the total length of terminal axon arbors in hypothyroid rats.
This arrested growth was also reflected by a 58% reduction in
the number of buttons per terminal (Figure 3I). In hypothyroid
rats, ramification of the thalamocortical axons would appear to
be stalled postnatally, resulting in reduced synaptogenesis as sug-
gested by the reduced number of buttons in thalamocortical axons
[Ref. (246); Figure 3I] and in a decreased number of spines along
the apical shafts of the hypothyroid pyramidal cells (250). All of the
above data show that many target pyramidal cells fail to reach their
correct cortical location, not only failing to complete their normal
maturation but also that the afferents have arrested growth. In
fact, GAP-43 is downregulated, while Sema3A is upregulated in
developmentally hypothyroid and hypothyroxinemic pups (251).
In agreement, GAP-43−/− mice failed to express 5-HTT in the
barrel cortex causing a disrupted segregation of thalamic afferents
in the barrel cortex. In addition, recent data show that the den-
sity of VGluT1-immunoreactive buttons is decreased in layer IV
of the parietal cortex of hypothyroid rats (180). These data show
that there is an asynchrony in the maturation of thalamocortical
afferents and their cortical targets in hypothyroid rats. Cortical
cells could be at a stage of maturation that does not allow them to
respond to thalamocortical signals, resulting in abnormal commu-
nication between thalamic axons and target cells (e.g., by reduced
synaptogenesis). Hypothyroidism seems to dissociate stabilization
of juvenile axons from maturation, growth in caliber and myeli-
nation, processes, which were previously thought to be necessarily
linked (134, 232, 252).
Abnormal patterns of connectivity have been also found in the
hippocampus of developmentally hypothyroid rats (193). These
authors found in the hippocampus of pups born to hypothy-
roid dams that CA pyramidal neurons developed atrophic apical
(15% shorter) and fewer number of ramifications (about 31 and
36% less in dentate gyrus and CA, respectively). Blurred layering
and heterotopic neurons were also found in the hippocampus of
pups born to hypothyroxinemic pregnant rats [Ref. (158, 164);
Figure 2B]. Decreased mossy fiber zinc density (33–45% reduc-
tion) was found in perinatal hypothyroid rats after PTU treatment
from E18 to P31 (253) and in postnatal hypothyroid rats (254).
P40 pups born to late hypothyroid dams (thyroidectomized by
E16; LMH pups), showed a 41.5% decrease in the Zn-positive
area in the stratum oriens, in parallel to down expression of
the Zn transporter-3 (ZnT-3; Figure 3E) and reduced density
of VGluT1-immunoreactive buttons (Figure 3F). In addition,
pCreb/pATF1, pCreb/Creb, pErk1/Erk2, and pErk2/Erk2 ratios in
the hippocampus decreased in LMH pups (59.1, 66.7, 44.4, and
42.9%, respectively) [Ref. (169); Figures 3J,K]. Recently, the hip-
pocampus of developmentally hypothyroid pups showed altered
VGluT1/VGAT immunoreactivity (180). Although Camk4/Creb
pathway plays a fundamental role in neurites growth and estab-
lishment of synapses, other genes are involved in the develop-
ment of hippocampal connections. It has been found that the
T3-regulated BDNF is involved in the regulation of the trans-
lational expression of VGluT1 in cultured hippocampal neurons
(255, 256). Interestingly, BDNF was also found involved in the acti-
vation of Erk1/2 signaling pathway (188), which affects not only
the differentiation of hippocampal neurons but also almost all
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FIGURE 3 |Thyroid hormones affect connectivity, maturation, and
function of the cerebral cortex. (A,B) Collages from confocal photo-
micrographs (taken with the ×20 objective) showing double immunolabeling
for Camk4 [red; (A)] and Nurr1 [green; (B)] in the parietal cortex of P10
control (C), LMH (pups born to dams thyroidectomized at E16), and MMI
(MMI treatment starting at E10) pups. Most of Camk4-immunoreactive
neurons were located in layers II–IV and upper layer V. Numerous
(Continued)
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FIGURE 3 | Continued
Camk4-immunoreactive neurons can be seen in layer VIb of P10LMH and
P10MMI pups (arrows) compared with P10C pups. At P10, about 60% of
Camk4-immunoreactive neurons of layer VIb are also Nurr1-immunoreactive.
(C) Photomicrographs of coronal sections of the parietal cortex showing
NeuN-immunoreactive neurons in C and LMH pups at P15. At P15, the
border between the subplate and adjacent layer VI is more clear-cut in LMH
than in C pups, showing that a remaining subplate is still present.
(D) Photomicrographs of flattened neocortex tangential sections showing
5-HT immunostaining in the posteromedial barrel subfield of the parietal
cortex of C and MMI rats at P4 and P15. At P4, heavily immunostained barrels
can be seen. Decay of 5-HT labeling occurs by P11 in C and by P16 in MMI
rats. Note that in P15C rats, no barrels were immunostained, whereas in
P15MMI rats, they are still immunopositive. (E) Photomicrographs of coronal
sections of the area CA3 of the hippocampus showing the Zn-labeling of
mossy fibers in C and LMH pups at P40. Note the heavier labeling of mossy
fibers in the stratum oriens (arrowhead) of CA3 in C compared with LMH
pups. (F) Confocal deconvoluted images of vesicular glutamate transporter
type 1 (VGluT1, which labels excitatory buttons) of the stratum radiatum (rm)
in CA3 in C and MMI rats at P50, labeling mossy fiber buttons. Note the
decreased density of immunoreactive buttons in P50MMI pups compared to
controls. (G) Photomicrographs of coronal sections from P4 and P7 MMI rats
that had the lipophilic carbocyanine DiI tracer (1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate) implanted in the ventro-basal
thalamic nucleus. At P4, DiI-labeled thalamic afferents enter the
somatosensory cortex, and form clusters in layer IV. At P7, collaterals in layer
IV form more dense clusters than at P4. These images show that hypothyroid
thalamic axons reach their somatosensory target areas as in normal rats. (H)
Coronal views of thalamocortical terminal arbors in layer IV in the
posteromedial barrel subfield of C and MMI rats at P60. The barrel limit is
marked with dashed lines. Note that in MMI rats terminal arbors have shorter
and tortuous branches. (I) Histograms representing mean values for the
number of axon segments per terminal (upper), segment length (middle), and
buttons per segment (bottom) in C (white bars) and MMI (black bars) rats for
each segment order. Note that in general MMI mean values are lower. (J,K)
Western blots obtained from the hippocampus of C and LMH pups at P40,
immunolabeled for ERK2, pERK1, and pERK2 (J) and pATF1, pCREB, and
CREB (K). Histograms showing that the pERK1/ERK2 and pERK2/ERK2 (J)
and pCREB/pATF1 and pCREB/CREB (K) ratios are reduced by 44.4, 42.9,
59.1, and 66.7%, respectively, in LMH compared with C pups. (L) Histogram
showing step-down latencies in seconds at 1, 3, and 24 h after the initial foot
shock in C and LMH pups at P39. Pups from LMH dams show 24.9%
reduction in the step-down latency at 1 h after the foot shock. (J–L) Error bars
represent±SD; n.s., no significant differences; *P <0.001 for LMH compared
with C group. (A,B) Modified from Navarro et al. (239). (C,E,J,K,L) Modified
from Berbel et al. (169). (D,G,H,I) Modified from Ausó et al. (246).
aspects of corticogenesis (Tables 3–6). However, the inactivation
of other pathways such as the Gsk3β/CRMP2 pathway will result in
delayed axonal growth (251, 257). Decreased p-Gsk3β labeling and
increased labeling of its inactivated p-CRMP2 target protein was
seen in the developmentally hypothyroid and hypothyroxinemic
rat hippocampus (251).
Altered postnatal synaptogenesis has been observed in the
molecular layer of the cerebellar cortex of hypo- and hyper-
thyroid rats (214). Neurotrophins BDNF and NT3 are down-
expressed in postnatal PTU treated rats, resulting in atrophy of
Purkinje cell dendrites and in a decreased number of synapses
(258) and BDNF is also downexpressed in the hippocampus
of developing hypothyroid rats (256). However, neurotrophins
might have a dual role in developing and adult hypothyroid rats,
because, BDNF is highly expressed in layers II, III, and V of
the neocortex and in all hippocampal areas of adult hypothy-
roid rats (259). These authors observed an increased number
of apoptotic neurons and astrocytes in the adult hypothyroid
cortex, and they suggested that the increase of BDNF in the
hypothyroid adult neocortex and hippocampus might have a
protective role against cellular stress associated to degenera-
tive processes. Interestingly, in young and adult autistic human
cerebellar samples (ages ranging from 7.5 to 34 years) a 40.3%
increase in NT3 expression was found (260). Other T3-regulated
genes, involved in synaptogenesis, plasticity, and neurotransmis-
sion, have been found [Ref. (23, 44); Tables 4 and 5]. The T3-
regulated ANXA6 gene codes for the calcium-binding protein
annexin 6 that may play a structural role in facilitating mem-
brane association at the cisternal organelle level and/or in sta-
bilizing IP3R1 microdomains in the axonal initial segment of
hippocampal neurons (261). NR4A1 codes for the transcription
factor Nurr77 that mediates in mechanisms of long-term synaptic
plasticity in the hippocampus and consequently, in the consol-
idation of long-term hippocampus-dependent memory (262).
PACSIN2 codes for protein kinase C and casein kinase substrate in
neurons protein 2, which interacts with dynamin and synapsin,
which affect the recruitment of synaptic vesicles (263), while
TGB2 codes for transforming growth factor-beta 2, which is
involved in the differentiation of granule neurons of the dentate
gyrus (188).
Structural changes in the cerebral cortex result in altered
electrophysiology and behavior of thyroid deficient rats. Most
of the electrophysiological studies have been performed in the
CA1 hippocampal area. Decreased long-term potentiation (LTP)
was shown in developing rats with severe and chronic hypothy-
roidism (166, 264), as well as in adult hypothyroid rats (265).
Altered LTP was also observed in pups born to rats treated with
MMI from E12 to E15 (266). Recent studies have shown that
developmental hypothyroidism decreases the number of burst-
ing CA1 cells, as well as the number of spikes per burst, resulting
from altered low-threshold Ca2+ current (267). As mentioned
above, the growth of axon caliber was arrested in the anterior
commissure and the corpus callosum of hypothyroid rats (225,
228), which might be relevant for the signal transmission veloc-
ity of commissural axons (268). The behavior of hypothyroid
rats related to cerebral cortex alterations are mainly based on
tests to measure (i) locomotor functional excitability and seizure
susceptibility (158, 218, 221, 269), and (ii) learning, attention,
and memory deficits (169, 219, 264, 266, 270, 271) (Figure 3L).
Despite the differences between rodent and human cerebral cor-
tices, these studies might be useful to find morphofunctional
alterations in hypothyroid rodents that might also occur in neu-
rological and mental disorders associated to hypothyroidism in
humans, such as ASD and ADHD. Significant T3-regulated genes,
involved in memory and behavior have been found [Ref. (23,
44); Table 6]. Among these, ADCY8, ADRBK2, and GRK5 code
for proteins associated to G-protein signaling (272–274). The
transcription factors DBP, involved in kainite-involved seizures
and hippocampal plasticity (275), and NR2A1 were mentioned
above.
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ASD AND THYROID HORMONES DURING BRAIN
DEVELOPMENT
Experimental studies in rodents clearly show that thyroid hor-
mone deficiency results in delayed, temporarily, or permanently
suppressed, or abnormal, connections, resulting in behavioral
and brain dysfunction (10). Abnormal morphophysiological and
behavioral traits established during gestation and early postnatal
ages might be maintained throughout life and thereby be a risk
factor for the development of behavioral and mental disorders
later in life.
Despite differences resulting from age at autopsy and the con-
comitant effects of seizures and of intellectual disability of variable
severity, a substantial body of evidence has accumulated since the
1970s on the fundamental morphological changes affecting the
brain of patients with ASD (276, 277). Wegiel et al. (278) reviewed
available neuropathological data and concluded that ASD results
from dysregulation of the normal mechanisms of neurogenesis
and neuronal migration, plus dysplastic changes and defects of
neuronal maturation. Thus, the neuropathology of ASD is consis-
tent with a prenatal time of onset. A likely etiological hypothesis
posits that ASD may be caused by thyroid hormone deficien-
cies during cerebral cortex development, either due to a genetic
deficiency of the TRIP8 gene (thyroid receptor interacting pro-
tein), which codes for a transcriptional regulator associated with
nuclear thyroid hormone receptors (279) or associated to mater-
nal hypothyroidism, which increases fourfold the risk of ASD in
the child (3, 63).
The morphological brain changes and the genes found to be
transcriptionally or functionally involved in ASD will be briefly
reviewed here, both from post-mortem data and from in vivo
imaging, along with a summary of the neurotransmitters affected.
Finally, the relevance of thyroid hormones in accepted animal
models of ASD is presented. Thyroid hormone deficiency dis-
eases and ASD share common altered gene pathways and comor-
bid disorders, and epidemiological studies reported a relation-
ship between thyroid hormone deficiency and ASD, although
morphofunctional differences between these two conditions exist.
BRAIN ALTERATIONS
Young children with ASD are megalencephalic, with increased
brain size and weight (276, 277). Brain imaging data and head cir-
cumference studies have shown two phases of early brain growth
in ASD pathology: early brain overgrowth during the first postna-
tal years and arrest of growth during early childhood (280), which
might be overlapped with neuronal degeneration in some brain
regions by preadolescence and continued into adulthood (280,
281). Increased number of neurons could contribute to increase
brain volume. Macroscopically and on imaging, the cerebral cor-
tex in ASD exhibits an abnormal pattern of convolutions (282)
involving the orbitofrontal cortex (283) and the temporal lobes
with hyperconvoluted hippocampus (276). Counts performed in
Nissl stained sections suggests increased density of cells in the
frontal cortex (284). However, other factors, besides of the increase
in the number of neurons, can contribute to increase brain vol-
ume. Increased cerebrospinal fluid volume, and slight reductions
of gray and white matter volume in frontal, temporal, and parietal
lobes have been reported (285). In addition, recent studies have
shown focal brain inflammation (286, 287) and increased gliosis
subjacent to neuronal degeneration (281). Changes do not affect
the brain uniformly, i.e., the fusiform face area and the limbic
system have increased cell packing density and smaller neuronal
size involving hippocampus, subiculum, and amygdala, and to a
lesser extent the entorhinal cortex, mammillary bodies, and sep-
tal nuclei (277), while other areas are normal; for instance, the
posteroinferior occipitotemporal gyrus showed no differences in
pyramidal neuron number or size in layers III, V, and VI (288).
In Brodmann areas 44–45, Jacot-Descombes et al. (289) demon-
strated reduced pyramidal neuron size suggesting impairment of
neuronal networks relevant to communication and social behav-
iors. However, owing to the relatively small number of autistic
brains studied up to date and the enormous heterogeneity in
ASD phenotypes and comorbid diseases, more neuropathologi-
cal studies will be need for clarification of neuroanatomy of ASD
(107, 290).
Despite changes in brain volume in ASD, some anatomical
alterations are common with hypothyroid brains. Microscopic
examination reveals dysgenesis of the cerebral cortex (276, 277)
with increased cortical thickness, abnormal laminar patterns, high
density of hippocampal neurons, presence of neurons in the mol-
ecular layer, neuronal disorganization, poor differentiation of the
gray–white matter boundary, and neuronal heterotopias. Corti-
cal neurons are small, closely packed, lack dendritic arbors, and
appear immature; these changes are consistent with an arrest
of cerebral maturation (290, 291). Also, the cortical organiza-
tion is altered with narrower cortical minicolumns (292, 293).
The focal cortical dysplasia of ASD appears to result from loss
of synchronized radial and tangential migration of glutamatergic
and GABAergic neurons, respectively (294). The CNTNAP2 gene,
which codes for contactin associated protein-like 2, is expressed
in human frontal areas and has been found to be involved in
ASD and language impairment (295, 296). A finding consistent
with this view is the demonstration by Kotagiri et al. (297) of
cytoarchitectural changes in the ependymal cells of the subven-
tricular zone in ASD, with lower cell density in the septal but
not in the striatal zone. A subset of ependymal, astrocyte rib-
bon, and rostral migratory stream (RMS) cells expressed PCNA,
Ki67, PLP, and α-tubulin. In addition, the white matter shows
areas of focal increase in the number of heterotopias, reflect-
ing abnormal neuronal migration (278). Using imaging, Gozzi
et al. (298) showed that the magnetization transfer ratio of
the corpus callosum was significantly higher in children with
ASD than in normal controls, indicating abnormal myelination
in ASD.
According to a consensus by Fatemi et al. (299), reduction in
Purkinje cell and cerebellar granule cell density is consistently
observed in ASD (300), along with developmental abnormali-
ties of the inferior olives (301), consistent with abnormal neu-
ronal migration before the 3rd month of gestation. Purkinje cells
are decreased in the posterolateral neocerebellar cortex and the
archicerebellar cortex (302) with vermis hypoplasia on brain imag-
ing (303, 304). Using MRI tractography in children with ASD,
Jeong et al. (305) showed decreased fiber numbers connecting
cerebellar cortex to ventral and dorsal dentate nuclei confirming a
decrease in connectivity and numbers of Purkinje cells.
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NEUROTRANSMITTERS IN ASD
Perry et al. (306) investigated cholinergic biomarkers in the basal
forebrain, frontal cortex, and parietal cortex of children with ASD,
mental retardation, and epilepsy and found decreased binding of
the α4 nicotinic and the muscarinic M1 receptors (α4 nAChR and
m1AChR, respectively). In the cerebellum, Lee et al. (307) found
decreased α3 and α4 nAChR binding in granule cells, Purkinje
cells, and molecular layers along with increased α7 nAChR bind-
ing in the granule cell layer. Blatt et al. (308) found that only
the GABAergic system was significantly reduced in the hippocam-
pus in ASD; the serotoninergic, cholinergic, and glutamatergic
systems were normal. GABAA and GABAB receptor density in
the anterior cingulate cortex and fusiform gyrus is decreased
(309, 310). The dysregulation of the GABAergic system pathway
includes downregulation of GABAA and GABAB receptors (309–
311) and reduction of glutamic acid decarboxylase enzymes (312)
and metabotropic glutamate receptor type 5 [mGluR5; (313)].
FMRP and mGluR5 are reduced in cerebellar vermis and frontal
cortex in ASD (314, 315). In addition, 5-HT neurotransmission
has been found to be deficient in ASD; in particular, Oblak et al.
(316) showed decrease in 5-HT1A receptor and 5-HT2A receptor-
binding density, as well as in 5-HTT in posterior cingulate cortex
and fusiform gyrus. Mutations in the GABAA receptor subunit
have been associated with ASD and epilepsy (317).
Two relevant genes in the diagnosis of ASD are SHANK3 (318)
and GABRB3 (311). SHANK3 is a synaptic scaffolding protein
enriched in the postsynaptic density of excitatory synapses, and
plays important roles in the formation, maturation, and mainte-
nance of synapses. Several SHANK3 mutations have been identi-
fied in a particular phenotypic group of patients with ASD (318).
A study of the Danish Newborn Screening Biobank revealed levels
of BDNF in the lower 10th percentile during the neonatal period
in children later diagnosed with ASD (319). SHANK3 mutations
may be involved in ASD, cerebellar development, and cerebellar
vermis hypoplasia (320). GABRB3 codes for GABAAβ3 receptor,
and is downexpressed in brains of autistic children, particularly in
the cerebellum (311).
THYROID-RELATED GENES INVOLVED IN ASD
Recently, Betancur (321) concluded that despite the more than 100
genetic and genomic disorders associated with ASD, we still lack
a clear understanding of its pathogenesis. In 2007, Castermans
et al. (279) identified in a subject with ASD a de novo chro-
mosomal anomaly on chromosome 10q21.3 that disrupted the
TRIP8 gene and the nearby REEP3 gene that codes for receptor
expression-enhancing protein 3, which is a microtubule associ-
ated protein sequestering the endoplasmic reticulum away from
chromosomes during mitosis. The authors concluded that TRIP8
codes for a protein predicted to be a transcriptional regulator asso-
ciated with nuclear thyroid hormone receptors but noted that,“no
link between thyroid gland and ASD has been reported so far.”
We summarize in Tables 1–6 a list of relevant genes that have
been found to be T3-regulated at the transcriptional level in the
rodents cerebral cortex (149, 322), and their human homolog
genes (marked in bold) that have been found mutated in ASD
patients. The list is far to be exhaustive and, most probably, the
overlapping between T3-regulated and ASD-mutated (T3/ASD)
genes will increase in the near future. Relevant are Creb/Crem
transcription factors that are involved in all critical events of cor-
ticogenesis, and Camk4 and Erk1/2 kinases that participate in
the Camk4/Creb/Crem and Erk1/2/Creb/Crem signaling pathways
(44, 183, 323–325).
As mentioned earlier, critical events at the beginning of cor-
ticogenesis are cell division and differentiation of neuroblasts to
become young migrating neurons, and the migration of young
neurons to their final destinations. T3/ASD genes involved in
cell division and differentiation (Table 1) are CTNNB1 codes
for β-catenin that is involved in the transition of epithelial-
to-mesenchymal transition (symmetrical-to-asymmetrical divi-
sions; see above) and in the astrocytes’ differentiation (326);
DYRK1A codes for dual specificity tyrosine-phosphorylation-
regulated kinase 1A, which is a regulator of brain growth (196);
GNB1L code for a 6 WD40 repeats-containing protein most likely
involved in cell cycle regulation (327); and FLT1 that codes for
vascular endothelial growth factor receptor 1, a tyrosine kinase
involved in the control of cell proliferation and differentiation
in angiogenesis and neurogenesis; FLT1 has been found reduced
in severe autism (328). T3/ASD genes involved in cytoskele-
ton organization and cell migration (Table 2) are GNAS that
codes for G-protein α subunit (Gs-α) (329); FN1 that codes for
fibronectin, an extracellular matrix protein involved in cell adhe-
sion and migration, found increased in serum of children with
autism (330); SERPINH1 that codes for heat shock protein 47 that
binds collagen and was found abnormally expressed in the tem-
poral cortex of ASD patients (331); and NEFH, NEFM, and NEFL
code for neurofilament subunits and has been found altered in the
frontal cortex neurons in children with autism (332). The genes
involved in the reelin signaling pathway include RELN (reelin),
DAB1 (disabled-1), VLDLR (very-low-density-lipoprotein recep-
tor) (331–335), and PAFAH1B1 (platelet-activating factor acetyl-
hydrolase IB subunit α; Lis1) that interacts with dimein and
VLDLR. Fatemi et al. (312) reported decreased blood levels of
reelin in children with ASD. Also, using post-mortem material
from superior frontal, parietal, and cerebellar cortex from autis-
tic brains and matched controls, significant reductions in reelin
protein, reelin mRNA, and dab1 mRNA along with elevations
in VLDLR mRNA in frontal and cerebellar cortex, indicative
of impairments in the reelin/dab1 signaling pathway in ASD
were observed (336). Genetic susceptibility polymorphisms of
the RELN gene have been described in ASD (337–340), although
other studies have been negative (341–344). A recent meta-analysis
by Wang et al. (345) revealed that the RELN variant rs362691,
rather than rs736707 or the GGC repeat variant, might contribute
significantly to ASD risk.
The T3/ASD genes involved in neurite development and mat-
uration (Table 3) are ANK3 that codes for ankyrin-3, which
participates in the recruitment of voltage-gated sodium channels
at the axon hillock and node of Ranvier (346); ARX that codes
for the transcription factor Aristaless-Related Homeobox, associ-
ated to several neurological and psychiatric disorders, including
ASD (347, 348); BDNF has high-affinity for TrkB receptor and
is involved in neurite development, neuronal plasticity, LTP, and
apoptosis of CNS neurons (348, 349); CNTN4 codes for contactin-
4, an Ig-cell adhesion molecule involved in the development
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and plasticity of neuronal circuits (350); NOS1 codes for nitric
oxide synthase 1 that is involved in glutamate-mediated neu-
rotransmission and toxicity (351); FLT1, FN1, and NEFs were
mentioned above. T3/ASD genes involved in synaptogenesis and
plasticity (Table 4) are ATP2B2 that codes for plasma membrane
calcium-ATPase, involved in the translocation of calcium to the
endoplasmic reticulum (352); NRGN that codes for neurogranin,
involved in synaptic plasticity and LTP (353); BDNF, CNTN4, and
PAFAH1B1 mentioned above.
The T3/ASD genes involved in neurotransmission (Table 5)
are HOMER1 that codes for homer protein homolog 1, is a major
component of postsynaptic density involved in metabotropic glu-
tamate receptor signaling (354); KCNJ10 that codes for ATP-
sensitive inward rectifier potassium channel 10, involved in axonal
membrane repolarization (355); NTS that codes for neurotensin
is involved in modulation of dopamine signaling and focal brain
inflammation, and was found increased in serum of ASD chil-
dren (286); SLC17A7 codes for vesicular glutamate transporter 1
(VGluT1), and is involved in glutamatergic transmission (333);
NRGN and PAFAH1B1 were mentioned above.
The T3/ASD genes involved in memory and behavior (Table 6)
are CALB1 and PVALB that encode calbindin-D28k and parvalbu-
min, respectively, are involved in GABAergic transmission (332);
HTR7 that codes 5-HT7 receptor is involved in serotonin sig-
nal transduction (333, 356); HOMER1, NOS1, and NTS were
mentioned above.
ANIMAL MODELS OF ASD
A number of animal models of ASD are the result of inser-
tion/deletion of different ASD-related genes and exposure to envi-
ronmental factors [reviewed by Gadad et al. and Provenzano et al.
(357, 358)]. Sadamatsu et al. (359) proposed the rat with mild
and transient neonatal hypothyroidism as a novel model for ASD.
Other models include the repetitive behavior observed in C58/J,
C57BL/6J, and Grin1 knockdown mice (360). The homeobox-
containing transcription factor engrailed-2 (En2) is involved in
patterning and neuronal differentiation; Sgadò et al. (361, 362)
showed that adult En2−/−mice exhibit reduced brain interneuron
expression of GABAergic marker mRNAs, and reduction in par-
valbumin, somatostatin, and neuropeptideY in the cerebellum and
cerebral cortex (including hippocampus). The genetically inbred
BTBR T+Itpr3tf/J mouse model of ASD exhibits social impair-
ment and stereotypic behavior suggestive of mTOR overactivation
(363). The BTBR model shows extensive anatomical abnormalities
in the white matter of the corpus callosum and the hippocam-
pal commissure (364). Uchino and Waga (365) identified novel
SHANK3 transcripts whose transcription started at the vicinity of
the CpG-island 2 in the mouse brain and developed the Shank3
mutant mice that exhibit autistic-like behaviors. Waga et al. (366)
identified two different amino-terminus truncated Shank3 tran-
scripts, Shank3c-3 and Shank3c-4, expressed from the intron 10
of the Shank3 gene, and suggested the epigenetic regulation of
the expression of these transcripts via methyl CpG-binding pro-
tein 2 (MeCP2). Interestingly,MeCP2 mediates activity-dependent
regulation of synaptic strength during the process of circuit for-
mation and prevents uncontrolled recurrent excitation that may
result in a pathophysiological increase of neuronal excitability,
aberrant network activity, and seizures, which are common Rett
patients (182).
The valproic acid model of ASD has become widely used (367–
371). However, it is not widely known that valproic acid at the
usual therapeutic doses used for the treatment of epilepsy has
anti-thyroid effects (372) and induces hearing loss in patients
(373).
CONCLUSION
Thyroid hormones exert both genomic and non-genomic actions
in many tissues,organs,and systems over the course of a lifetime. In
particular, they are crucial during early neurodevelopment, since
key phases of the CNS development depend of the expression
of thyroid hormones regulated genes. These genes affect, among
other things, proliferation, migration, and maturation of neu-
rons and glial cells, which under certain circumstances can result
in abnormal connectivity, and consequently in behavioral dys-
function. Morphofunctional alterations caused during pregnancy
and early postnatal are permanent, and thus they are a risk fac-
tor for the development of behavioral and mental disorders later
in life. The knowledge of how thyroid hormones regulate these
phases of development may help to understand altered regulatory
mechanisms in neurodevelopmental diseases such as ASD, ADHD,
schizophrenia,and epilepsy with cytoarchitectonic alterations sim-
ilar to those found in hypothyroidism and hypothyroxinemia and
vice versa. By combining basic and clinical investigation, new data
will be obtained to better understand the basic phases of brain
development and the genetic and physiological events underly-
ing some of the human diseases mentioned above. Despite of
obvious differences between humans and other mammals in cor-
tical organization and function, animal models might be a useful
tool to approach the understanding of common etiological factors
in hypothyroidism and ASD since, as the evo-devo tell us, both
rodents and humans share homologous gene pathways involved
in these diseases.
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